Unknown

Dataset Information

0

Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?


ABSTRACT: Familial hypercholesterolemia (FH) is caused by mutations in LDLR (low-density lipoprotein receptor), APOB (apolipoprotein B), PCSK9 (proprotein convertase subtilisin/kexin type 9), or APOE (apolipoprotein E) genes in approximately 80% of the cases. Polygenic forms of hypercholesterolemia may be present among patients clinically diagnosed with FH but with no identified mutation (FH mutation-negative (FH/M-)). To address whether polygenic forms may explain phenocopies in FH families, we calculated a 6-single-nucleotide polymorphism (SNP) genetic risk score (GRS) in all members from five French FH families where a mutation was identified (FH/M+) as well as some phenocopies (FH/M-). In two families, three FH/M- patients present a high GRS suggesting a polygenic hypercholesterolemia for these phenocopies. However, a high GRS is also observed in nine FH/M+ patients and in four unaffected relatives from three families. These observations indicate that the GRS does not seem to be a good diagnostic tool at the individual level. Nevertheless, the GRS seems to be a contributor of the severity of hypercholesterolemia since patients who cumulate a mutation and a high GRS exhibit higher low-density lipoprotein cholesterol levels when compared to patients with only FH (p?=?0.054) or only polygenic hypercholesterolemia (p?=?0.0039). In conclusion, the GRS can be used as a marker of the severity of hypercholesterolemia but does not seem to be a reliable tool to distinguish phenocopies within FH families.

SUBMITTER: Ghaleb Y 

PROVIDER: S-EPMC5891487 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications


Familial hypercholesterolemia (FH) is caused by mutations in LDLR (low-density lipoprotein receptor), APOB (apolipoprotein B), PCSK9 (proprotein convertase subtilisin/kexin type 9), or APOE (apolipoprotein E) genes in approximately 80% of the cases. Polygenic forms of hypercholesterolemia may be present among patients clinically diagnosed with FH but with no identified mutation (FH mutation-negative (FH/M-)). To address whether polygenic forms may explain phenocopies in FH families, we calculate  ...[more]

Similar Datasets

| S-EPMC9833269 | biostudies-literature
| S-EPMC9174089 | biostudies-literature
| S-EPMC7063643 | biostudies-literature
| S-EPMC11019987 | biostudies-literature
| S-EPMC7801205 | biostudies-literature
| S-EPMC10092380 | biostudies-literature
| S-EPMC3681171 | biostudies-literature
| S-EPMC3701840 | biostudies-literature
| S-EPMC5786657 | biostudies-literature
| S-EPMC4326701 | biostudies-literature